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Due to the nonmyeloablative nature of these regimens, most patients are mixed chimeras after allo-SCT with both donor and residual patient hematopoiesis present.
Intravenous fludarabine is used in many RIC protocols, combined with either low-dose TBI or different combinations of cyclophosphamide, busulfan, melphalan or antithymocyte globulin. 1 An oral formulation of fludarabine has become available, which, however, was reported to have a large interindividual variation in systemic bioavailability of 30-80%. 2 The use of oral fludarabine may, therefore, potentially affect engraftment or may result in diminished donor hematopoiesis.
We use a RIC regimen consisting of intravenous fludarabine 30 mg/m 2 (days -10 to À5), busulfan 3.2 mg/kg (days À7 and À6) and horse antithymocyte globulin 10 mg/kg (days -4 to À1), in combination with alemtuzumab (20 mg) added to the stem cell graft for T cell depletion. 3 Between 2000 and 2005, we performed RIC SCT with peripheral blood stem cells in 64 patients for various indications (acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, low-grade and aggressive non-Hodgkin's lymphoma, severe aplastic anemia, myeloma, renal cell carcinoma and breast carcinoma). Initially, transplants were only performed in sibling patient-donor combinations using intravenous fludarabine. From 2002, fludarabine was switched to the oral formulation (50 mg/m 2 , days -10 to À5) using both related and unrelated donors.
Oral fludarabine was well tolerated, 92% of patients became neutropenic and 70% became thrombopenic. Platelet and granulocyte recovery times after SCT were identical in the patient groups (Table 1) . Nonengraftment was observed in one patient transplanted with an unrelated donor. In all patient groups high percentages of donor chimerism were observed 1 month after transplantation ( Figure 1 ). Nonparametric statistical analysis with the Mann-Whitney test did not show significant differences between the patient groups.
We conclude that in a RIC regimen consisting of fludarabine, busulfan, antithymocyte globulin and alemtuzumab added to the graft, administration of oral instead of intravenous fludarabine did not affect engraftment and donor chimerism. The use of the oral fludarabine formulation shortened the duration of hospital admission by 3 days. A further reduction of Table 1 Median platelet and neutrophil recovery times from the start of conditioning hospital admission days may also be achieved by using oral busulfan. The use of oral fludarabine in RIC regimens may help to convert allo-SCT into an outpatient's procedure.
